Ultimovacs ASA – Disclosure of voting rights of Extraordinary General Meeting
Oslo, January 6, 2025: In connection with the Extraordinary General Meeting of Ultimovacs ASA to be held on January 9,…
0,161€
-5,85%
Echtzeit-Aktienkurs Ultimovacs ASA
Bid:
Ask:
Nachrichten zur Ultimovacs ASA Aktie
Ultimovacs ASA: Regarding the extraordinary general meeting on 9 January 2025
…
Key information relating to the potential subsequent repair offering to be carried out by Ultimovacs ASA
Reference is made to the stock exchange announcement by Ultimovacs ASA ("Ultimovacs" or the "Company") on 17 December 2024 regarding…
Ultimovacs ASA – Mandatory notification of trade
Reference is made to the stock exchange announcement by Ultimovacs ASA (the "Company") on 17 December 2024 regarding the agreement…
Ultimovacs ASA Reports Third Quarter 2024 Financial Results and Provides General Business Update
Oslo, November 6, 2024: Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical-stage biotechnology company developing novel immunotherapies against cancer, announces its…
Ultimovacs ASA Reports Second Quarter 2024 Financial Results and Provides General Business Update
Oslo, August 21, 2024: Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical-stage biotechnology company developing novel immunotherapies against cancer, announces its…
Ultimovacs ASA announces revised terms of the employee share option program
Oslo, June 24, 2024: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology company developing immunotherapeutic cancer vaccines, announces revised terms…
Ultimovacs provides update from Phase I study in malignant melanoma: Continued strong overall survival in patients treated with UV1 cancer vaccine and pembrolizumab
Oslo, June 11, 2024: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology company developing immunotherapeutic cancer vaccines, today announced encouraging…
Ultimovacs ASA: Invitation to first quarter 2024 results webcast presentation
Oslo, April 30, 2024: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology company developing immunotherapeutic cancer vaccines, invites to a…
Ultimovacs ASA – Disclosure of voting rights of Annual General Meeting
Oslo, April 15, 2024: In connection with the Annual General Meeting of Ultimovacs ASA to be held on April 18,…
Ultimovacs to Present Poster at the American Association for Cancer Research (AACR) Annual Meeting 2024
Oslo, April 4, 2024: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology company developing immunotherapeutic cancer vaccines, today announces that…
Ultimovacs ASA: Mandatory notification of trades by primary insider
Oslo, 9 March 2024: Langøya Invest AS, a closely related party of Ketil Fjerdingen, a board member and primary insider…
Ultimovacs ASA: Mandatory notification of trade by primary insiders
Oslo, 7 March 2024: Langøya Invest AS, a closely related party of Ketil Fjerdingen, a board member and primary insider…
Ultimovacs Announces Topline Results from INITIUM Study Evaluating UV1 Vaccination Added to Ipilimumab and Nivolumab in Patients with Unresectable or Metastatic Malignant Melanoma
Oslo, March 7 2024: Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical-stage biotechnology leader in novel immunotherapeutic cancer vaccines, today announced…
Ultimovacs announces publication of results from NIPU Phase II trial with UV1 vaccination in mesothelioma in European Journal of Cancer
NON-REGULATORY PRESS RELEASE…